Critical reviews in oncology/hematology
-
Crit. Rev. Oncol. Hematol. · Nov 2010
The influences of age and co-morbidities on treatment decisions for patients with HER2-positive early breast cancer.
To investigate the influences of age and co-morbidities on the use of adjuvant chemotherapy and trastuzumab in patients with HER2-positive early breast cancer. ⋯ National variation in the use of adjuvant chemotherapy in women aged ≥70 years with high-risk breast cancer is substantial. Practice audits or clinical trials addressing the outcomes of systemic adjuvant therapy are needed for this ever-increasing population of patients.